| 2024-11-18 | +0.69 % |
|
| 2024-11-15 | -3.28 % |
|
| 2024-11-14 | -2.71 % |
|
| 2024-11-11 | -0.33 % |
|
| 2024-11-08 | +0.48 % |
|
| 2024-11-06 | -1.54 % |
|
| 2024-11-05 | +0.07 % |
|
| 2024-10-31 | -9.17 % |
|
| 2024-10-30 | -0.49 % |
|
| 2024-10-29 | -0.14 % |
|
| 2024-10-28 | -0.47 % |
|
| 2024-10-25 | +0.44 % |
|
| 2024-10-24 | -1.33 % |
- Regeneron Pharmaceuticals (REGN) stock fell by -1.33%, possibly due to market volatility or investor reactions to new disclosures, such as Lecap Asset Management Ltd. acquiring a small position in the company.
- Regeneron Pharmaceuticals (REGN) stock declined by -1.33% following Wells Fargo's downgrade of its price target from $1,200 to $1,050, despite maintaining an "overweight" rating for the company.
- Regeneron Pharmaceuticals (REGN) stock fell by 1.33% after OLD National Bancorp IN reduced its stake by 21.6%, indicating potential shifts in institutional investor sentiment.
- Regeneron Pharmaceuticals (REGN) stock fell by 1.33% after JPMorgan Chase & Co. reduced its price target from $1,200.00 to $1,150.00 while maintaining an "overweight" rating, indicating a potential decrease in expected value.
- Regeneron Pharmaceuticals (REGN) stock declined by 1.33% amid recent analyst updates on ratings and price targets, combined with insider stock sales potentially signaling a lack of confidence or volatility in its near-term outlook.
- Regeneron Pharmaceuticals (REGN) stock decreased by 1.33% after institutional investors adjusted their positions, with some hedge funds increasing their stakes while others hedged by selling shares, and mixed analyst ratings influencing market sentiment.
The drop in stock price is attributed to recent changes in institutional investments and varying analyst ratings that may have caused uncertainty among investors.
- Regeneron Pharmaceuticals (REGN) stock fell by 1.33% despite receiving an upgrade from analysts and several positive price target adjustments from various brokerages, indicating possible market reactions to broader economic factors or investor sentiment.
The decline in Regeneron's stock could be attributed to general market trends or investor profit-taking after steady increases, rather than specific negative news about the company.
|
| 2024-10-23 | -2.18 % |
|
| 2024-10-22 | -0.64 % |
|
| 2024-10-21 | -2.24 % |
|
| 2024-10-18 | -0.76 % |
|
| 2024-10-15 | +0.22 % |
|
| 2024-10-14 | -0.14 % |
|
| 2024-10-10 | -1.3 % |
|
| 2024-10-09 | +0.69 % |
|
| 2024-10-07 | -1.66 % |
|
| 2024-10-02 | -0.63 % |
|
| 2024-09-26 | +0.85 % |
|
| 2024-09-24 | -4.21 % |
|
| 2024-09-23 | -4.63 % |
|
| 2024-09-17 | -0.55 % |
|
| 2024-09-16 | -0.02 % |
|
| 2024-09-13 | -0.95 % |
|
| 2024-09-11 | +0.45 % |
|
| 2024-09-09 | +1.17 % |
|
| 2024-09-04 | +0.9 % |
|
| 2024-09-03 | -1.34 % |
|
| 2024-08-15 | +1.6 % |
|
| 2024-08-08 | +4.27 % |
|
| 2024-08-02 | -1 % |
|
| 2024-08-01 | +1.29 % |
- Regeneron Pharmaceuticals (REGN) stock rose by 1.29% due to positive investor sentiment amid a broader market rally driven by strong domestic economic factors and promising corporate earnings reports.
- Regeneron Pharmaceuticals (REGN) stock increased by 1.29% due to positive market momentum and trends in the healthcare sector that have bolstered investor confidence.
- Regeneron Pharmaceuticals (REGN) stock rose by 1.29% following the company's strong second-quarter earnings report, which featured an adjusted EPS of $11.56 and sales of $3.55 billion, both exceeding market expectations due to notable growth in its key drugs like EYLEA HD, Dupixent, and Libtayo.
- Regeneron Pharmaceuticals (REGN) stock rose 1.29% following strong second-quarter earnings results, where adjusted EPS of $11.56 and sales of $3.55 billion exceeded analyst expectations due to growth in their key products, including Dupixent and Libtayo.
- Regeneron Pharmaceuticals' stock rose by 1.29% following the announcement of strong second-quarter financial results, highlighted by a 12% revenue increase due to significant growth in its key products EYLEA HD, Dupixent, and Libtayo, along with a new regulatory approval for Dupixent in treating COPD.
The stock's increase can be attributed to the company's strong financial performance, positive momentum in sales growth, and advancements in its clinical pipeline, which fostered investor confidence.
|
| 2024-07-31 | +0.13 % |
|
| 2024-07-25 | +0.31 % |
|
| 2024-07-19 | -0.34 % |
|
| 2024-07-18 | -1.69 % |
- The article discusses the Capital Group Growth ETF (CGGR), highlighting its strong performance, diverse portfolio of stocks, and active management approach led by a team of experienced portfolio managers. The ETF has outperformed the broader market, including the Vanguard S&P 500 ETF, since its inception in early 2022. However, it does come with a slightly higher expense ratio of 0.39% due to its active management. The article also mentions that CGGR holds 103 stocks, including top holdings such as Meta Platforms, Microsoft, Netflix, Tesla, and Regeneron Pharmaceuticals (REGN). As for REGN stock specifically, it was down by -1.69% last night, with the reason for the decline not explicitly stated in the summary.
|
| 2024-07-12 | +1.83 % |
|
| 2024-07-10 | +1.62 % |
|
| 2024-07-08 | +1.74 % |
|
| 2024-06-28 | +0.02 % |
|
| 2024-06-26 | -0.19 % |
|
| 2024-06-18 | -0.6 % |
|
| 2024-06-14 | +0.97 % |
|
| 2024-06-13 | -0.11 % |
|
| 2024-06-11 | +0.88 % |
|
| 2024-06-06 | -0.51 % |
- The article discusses the decline of Regeneron Pharmaceuticals (REGN) stock by -0.51%, and the reason behind this decrease could be attributed to the known and unknown risks, uncertainties, and various important factors in the pharmaceutical industry, as mentioned in the article such as delays in clinical trials, inability to demonstrate safety or efficacy, competition, regulatory challenges, changes in strategy, and other external factors that may impact the company's performance and stock price.
- The article discusses various companies in the biotech sector with key clinical candidates in their pipelines, highlighting developments and studies of products such as DNAbilize by Bio-Path, ICE by Affimed, pamrevlumab and roxadustat by FibroGen, EQ101 by Equillium, AdenoVerse by Precigen, Berubicin by CNS Pharmaceuticals, avasopasem and rucosopasem by Galera Therapeutics, and products by other companies like Liquidia Corporation and Cyclacel. Recent news includes Equillium's Phase 2 study results for EQ101 in alopecia areata, Amarin's appointment of a new CEO and changes in Vascepa coverage, Bio-Path's Phase 2 study results for prexigebersen in acute myeloid leukemia, and FibroGen's FDA clearance for FG-3165 development in solid tumors. Regeneron Pharmaceuticals (REGN) stock went down by -0.51% last night possibly due to various factors affecting the biotech industry and individual company developments in the sector.
- Goldman Sachs revised its rating for 2Seventy Bio Inc. (NASDAQ:TSVT) stock to Sell with a $2.00 price target due to competition from Johnson & Johnson and Legend Biotech, challenges in market share, concerns over cost structure, and limited pipeline optionality after selling its pipeline to Regeneron Pharmaceuticals (REGN), impacting the stock value of Regeneron Pharmaceuticals (REGN).
|
| 2024-06-05 | +1.27 % |
- Summary: The article discusses the annual report of The Biotech Growth Trust PLC for the year ended 31 March 2024, highlighting its financial performance, investment strategy, exposure to various biotech companies, capital structure, revenue return, board changes, and upcoming events like the annual general meeting and proposed changes in benchmark index.
Regeneron Pharmaceuticals (REGN) stock went up 1.27% likely due to positive news or developments related to the company, such as advancements in its drug pipeline, successful clinical trial results, regulatory approvals, or strong financial performance.
- Regeneron Pharmaceuticals (REGN) stock went up by 1.27% last night despite facing an investigation by the U.S. Department of Justice for alleged False Claims Act violations related to failing to report discounts provided to drug distributors, resulting in inflated drug prices above Medicare limits.
|
| 2024-06-03 | +0.95 % |
|
| 2024-05-31 | +1.06 % |
- The article discusses that Regeneron Pharmaceuticals (REGN) stock went up by 1.06% following the announcement of the U.S. Food and Drug Administration (FDA) extending the target action date for the review of Dupixent as a treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD). The stock went up due to the positive developments in the review process and the potential approval of Dupixent for the COPD indication.
- Regeneron Pharmaceuticals (REGN) stock went up by 1.06% on the European regulator's backing for the use of Dupixent in patients with chronic lung disease, particularly COPD, as Sanofi and Regeneron expand the drug's potential applications, with the U.S. FDA requesting additional data, potentially leading to increased sales projections and growth prospects for the drug.
- The article discusses the FDA's extended review of Regeneron Pharmaceuticals' Dupixent for chronic obstructive pulmonary disease (COPD) with type 2 inflammation, highlighting positive trial results and ongoing regulatory submissions globally that could support approval, ultimately leading to a 1.06% increase in the company's stock. Regeneron's stock likely went up due to the positive outlook on the approval of Dupixent in COPD based on additional efficacy analyses and the company's commitment to bringing the treatment to patients with uncontrolled COPD quickly.
- Summary: Edmond DE Rothschild Holding S.A. reduced its stake in Regeneron Pharmaceuticals, Inc. by 9.0%, while several other hedge funds have recently bought shares of REGN; the stock rose by 1.06% last night, with the company's CEO and executive VP selling significant amounts of stock recently.
Reason for stock increase: The increase in Regeneron Pharmaceuticals' stock could be attributed to the positive sentiment surrounding the company, as evidenced by various institutional investors buying shares of REGN and analysts giving the stock high ratings and price targets, alongside the company's promising product pipeline and quarterly earnings performance.
|
| 2024-05-30 | +0.35 % |
- The article discusses how the stock of Regeneron Pharmaceuticals (REGN) rose by 0.35% overnight, with Congress Wealth Management LLC and other institutional investors acquiring shares of the biopharmaceutical company, indicating a positive investor sentiment and confidence in its growth prospects.
- Summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock was up 0.35% following Director Michael S. Brown's sale of shares, with current factors influencing the stock including quarterly earnings results and analyst ratings.
Reason for Stock Increase: The increase in Regeneron Pharmaceuticals stock could be influenced by positive analyst ratings and outlook, as well as potential positive sentiment around the company's recent quarterly earnings results.
- The article discusses how institutional investors like Orion Portfolio Solutions LLC decreased their positions in Regeneron Pharmaceuticals, Inc. (REGN) stock, while other large investors modified their holdings, and outlined insider selling activities. REGN stock likely went up due to positive ratings from various brokerages, such as Evercore ISI initiating coverage with an "outperform" rating and a $1,150.00 price target, as well as favorable earnings results.
- Regeneron Pharmaceuticals, Inc. (REGN) stock went up by 0.35% last night; however, the stock had previously experienced a decrease due to allegations by the U.S. Department of Justice that the company failed to report discounts provided to drug distributors, inflating the selling price of its Eylea drug above Medicare allowances.
|
| 2024-05-29 | -0.69 % |
|
| 2024-05-28 | -1.2 % |
|
| 2024-05-24 | +0.45 % |
|
| 2024-05-23 | -0.33 % |
|
| 2024-05-22 | -1.02 % |
|
| 2024-05-21 | +0.68 % |
- Regeneron Pharmaceuticals (REGN) stock went up last night by 0.68%, likely due to positive financial results and recent developments reported by Alvotech, a biotech company specializing in biosimilar medicines, including FDA approval of AVT04, a biosimilar to Stelara®, strategic partnerships, and positive study results for their biosimilar candidates.
- The article discusses Alvotech's financial results and recent corporate highlights, reporting increased revenue guidance for 2024, strategic partnerships, and positive clinical trial results, among other developments. Regeneron Pharmaceuticals (REGN) stock likely went up due to positive news from Alvotech, such as FDA approvals, commercialization agreements, and strong revenue forecasts, reflecting positively on the biotech sector as a whole.
- Regeneron Pharmaceuticals (REGN) stock went up by 0.68% last night and the article discusses a series of significant developments at Alvotech, a biotech company, which include obtaining FDA approval for multiple biosimilar medicines, signing strategic partnerships, and positive results from clinical studies, leading to raised revenue guidance for 2024, ultimately driving up investor interest and contributing to the increase in the stock price.
|
| 2024-05-20 | +0.51 % |
- The article discusses late-breaking data from the NOTUS phase 3 study on the use of Dupixent in adults with uncontrolled COPD, presenting positive results for the investigational biologic. Regeneron Pharmaceuticals' (REGN) stock likely went up due to the promising data on Dupixent's effectiveness in reducing exacerbations in COPD patients, potentially leading to a first-of-its-kind medical advancement for the COPD community pending regulatory approvals.
- Regeneron Pharmaceuticals (REGN) stock went up by 0.51% last night, potentially due to positive developments as there were no negative news highlighted in the article that would cause a decline in stock value like other companies mentioned in the investigation by Bragar Eagel & Squire.
- The article discusses an investigation by Pomerantz LLP into Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regarding potential securities fraud and unlawful business practices related to the company's failure to report discounts on its Eylea drug, leading to a stock price drop previously, and the stock went up 0.51% last night perhaps due to market speculation or positive news.
- The article discusses investigations involving various companies by the law firm Bragar Eagel & Squire, including Regeneron Pharmaceuticals (REGN), which is facing a DOJ lawsuit for allegedly failing to report discounts given to drug distributors, causing its stock to decline. The reason REGN stock went up by 0.51% last night was not mentioned in the provided article.
- The article discusses how Regeneron Pharmaceuticals' stock (REGN) increased by 0.51% after presenting positive late-breaking data from the NOTUS Phase 3 trial showing that their investigational drug, Dupixent (dupilumab), significantly reduced exacerbations by 34% and improved lung function in patients with uncontrolled COPD and type 2 inflammation, potentially providing a new medical advancement for the COPD community. REGN stock went up due to the promising results of Dupixent and its potential as a groundbreaking treatment for COPD.
|
